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ABSTRACT
The major human pathogen Mycobacterium tubercu-
losis can survive in the host organism for decades
without causing symptoms. A large cohort of Toxin–
Antitoxin (TA) modules contribute to this persis-
tence. Of these, 48 TA modules belong to the vapBC
(virulence associated protein) gene family. VapC tox-
ins are PIN domain endonucleases that, in enter-
obacteria, inhibit translation by site-specific cleav-
age of initiator tRNA. In contrast, VapC20 of M. tu-
berculosis inhibits translation by site-specific cleav-
age of the universally conserved Sarcin-Ricin loop
(SRL) in 23S rRNA. Here we identify the cellular tar-
gets of 12 VapCs from M. tuberculosis by applying
UV-crosslinking and deep sequencing. Remarkably,
these VapCs are all endoribonucleases that cleave
RNAs essential for decoding at the ribosomal A-site.
Eleven VapCs cleave specific tRNAs while one ex-
hibits SRL cleavage activity. These findings suggest
that multiple vapBC modules contribute to the sur-
vival of M. tuberculosis in its human host by reducing
the level of translation.
INTRODUCTION
The major human pathogen Mycobacterium tuberculosis,
the causative agent of tuberculosis (TB), currently infects
more than 8 million and kills >1 million people per year
(1). The prevalence of multi-drug resistant TB is increasing
and is a cause for significant concern (2).M. tuberculosis can
persist latently without symptoms for many years in human
carriers (3). The molecular mechanisms underlying latency
and slowed bacterial growth are still poorly understood but
may involve multiple regulatory pathways. One of these de-
pends on the stringent response and Toxin–Antitoxin (TA)
modules (4).
All bacteria produce slow growing ‘persister cells’ that
are tolerant to a broad spectrum of antibiotics (5,6). Re-
cent research on Escherichia coli and Salmonella shows that
persistence is controlled by the stringent response and TA
modules. Such TA modules are almost ubiquitous in bac-
teria and are often present in perplexingly high numbers
(7).Mycobacterium tuberculosis has at least 88 type II TAs
(8,9), raising important questions concerning their biologi-
cal function(s).
Type II TA modules encode two genes in an operon, a
protein ‘toxin’ that inhibits cell growth and a protein ‘an-
titoxin’ that counteracts the inhibitory effect of the toxin
by direct protein contact (10). The antitoxins are usually
metabolically unstable while the toxins are stable. Thus, reg-
ulated proteolysis of a given antitoxin determines the activ-
ity of the cognate toxin. Evidence from E. coli K-12 and
Salmonella indicates that TA modules are effector genes
that induce persistence when activated and step-wise dele-
tion of 10 type II TAs progressively reduced persistence
(11). Correspondingly, inactivation of Lon, the protease
that degrades all known type II antitoxins of E. coli K-
12, strongly reduced persistence. Remarkably, the TAs of E.
coli are induced stochastically by amechanism that depends
on (p)ppGpp, polyphosphate and Lon. In a population of
rapidly growing cells, approximately 10−4 have a high level
of (p)ppGpp that leads to accumulation of polyphosphate,
which activates Lon to degrade antitoxins. Toxin activation
then leads to growth arrest, multidrug tolerance, and per-
sistence (12). Independent support for this model has come
from several comprehensive studies of Salmonella enterica
serovar Typhimurium. S. Typhimurium has up to 20 type
II TAs and deletions of single TA loci showed reduced sur-
vival of S. Typhimurium within fibroblasts (13). Further-
more, deletion of single TA genes reduced persister cell for-
mation and survival when the bacterium was grown inside
macrophages (14). Consistently, multiple type II TAs have
been found to be activated inS.Typhimuriumwhen residing
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Figure 1. Known vapBC modules of Mycobacterium tuberculosis H37Rv,
growth-inhibition by selected VapCs and outline of the CRAC analysis
inside macrophages (15). Studies with M. tuberculosis also
support a role for TAs in persistence and virulence (8,16,17).
Mycobacterium tuberculosis has a highly expanded reper-
toire of TA modules, with 48 representatives of the vapBC
family (7,8) (Figure 1A). VapC toxins are PIN (pilT N-
terminal) endoribonucleases containing three or four con-
served acidic residues that coordinate Mg2+ ion(s) in the
active site (18). In Eukaryotes, PIN domains have been
identified in multidomain endonucleases involved in RNA
metabolism, RNA quality control and rRNA maturation
(19). In Prokaryotes, however, most PIN domain proteins
belong to the highly abundant VapC toxin family that
are present in staggering numbers in certain prokaryotic
genomes, includingM. tuberculosis (7–9).
The molecular targets of most prokaryotic VapCs are un-
known; however, the VapCs of S. Typhimurium, Shigella
flexneri and Leptospira interrogans cleave initiator tRNA
site-specifically in the anticodon loop, thereby inhibiting
global translation (20,21). In contrast, VapC20 of M. tu-
berculosis inhibits translation via cleavage of the conserved
Sarcin–Ricin loop (SRL) of 23S rRNA (22).
Here, we applied UV-induced RNA-protein crosslinking
and analysis of cDNA by high throughput sequencing
(CRAC) to identify transcriptome-wide targets of VapC
paralogues inM. tuberculosis usingM. smegmatis as a sur-
rogate host organism. First, we identified the cellular tar-
gets of six different VapCs and showed that they all cleave
tRNAs site-specifically within the anticodon loop. We then
used phylogenetic analysis to identify the cellular targets of
an additional six VapCs. Several of these VapCs were pre-
viously shown to have non-specific RNase activity in vitro
(23–25). Strikingly, we show that all 12 VapCs catalyse site-
specific cleavage of RNAs essential for protein synthesis.
MATERIALS AND METHODS
Strains, plasmids and growth conditions
Mycobacterium smegmatis strain MC2155 was routinely
grown in LB medium (Difco) containing 0.1% Tween-80
(LBT) at 37◦C. For UV-crosslinking experiments strain
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
procedure. (A) Chromosomal location of 48 vapBC modules (7,8). Genes
shown in blue are analysed here, gene shown in red was analysed previ-
ously (22). (B) Growth-inhibition tests of selected vapCs of M. tubercu-
losis in M. smegmatis strain MC2155 containing plasmid pMEND car-
rying a tetracycline inducible promoter and encoding C-terminally His-
TEV-FLAG tagged (HTF) vapC genes. Strain MC2155 carrying vapC4
(Rv0595c) vapC11 (Rv1561), vapC15 (Rv2010), vapC25 (Rv0277c), vapC26
(Rv0582), vapC28 (Rv0609), vapC29 (Rv0617), vapC30 (Rv0624), vapC32
(Rv1114), vapC33 (Rv1242), vapC37 (Rv2103c) or vapC39 (Rv2530c) were
grown overnight in LBT at 37◦C. The optical density (OD600) was then ad-
justed to 0.5, and the bacterial cultures serially diluted (10-fold) and spot-
ted (3l) on nutrient agar plates without orwith inducer (20 ng/ml tetracy-
cline). The plates were incubated 3 days at 37◦C. (C) Outline of CRosslink-
ing and Analysis of cDNA protocol (CRAC). (1) The HTF tagged VapC
protein is UV cross-linked (UV-C) with target RNAs in vivo, the RNA–
protein complexes are purified and the RNA trimmed by a cocktail of
RNase A/T1 and barcoded linkers are ligated to the RNA. (2) cDNA is
synthesized by reverse transcription using 3′-end specific primer and the li-
brary generated by PCR. (3) Finally, the DNA library is purified and deep
sequenced using the Illumina platform. The sequencing output is aligned
and analysed using the pyCRAC software package.
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MC2155 was grown inM9medium (Difco) containing 0.1%
Tween-80 (M9T)with 0.1%Casein hydrolysate, 1g/ml thi-
amine and 0.2% glucose as carbon source at 37◦C.When ap-
propriate, 50 g/ml kanamycin was added the medium to
maintain the plasmid. Furthermore, when stated 20 ng/ml
tetracycline was added to liquid or solid medium to induce
transcription from tetracycline inducible promoters.
Plasmids
Construction of plasmids is described in Supplementary
Information; Supplementary Table S1 contains a list of
oligonucleotides used to construct plasmids and to detect
RNAs in northern analysis.
Crosslinking and analysis of cDNA
Cultures (2 l) of M. smegmatis MC21555 contain-
ing plasmids pMEND::HTF, pMEND::vapC4::HTF,
pMEND::vapC11::HTF, pMEND::vapC28::HTF,
pMEND::vapC29::HTF, pMEND::vapC30::HTF,
pMEND::vapC37::HTF, were grown exponentially in
M9T at 37◦C under constant aeration. At OD600 = 0.3–0.4
cultures were induced by addition of 20 ng/ml tetracy-
cline. After 20 min of incubation cultures were irradiated
with 1800 mJ of UV-C for 100 seconds (Van Remmen
UV Techniek). The cells were subsequently harvested by
centrifugation, washed in ice-cold phosphate buffered
saline (PBS) containing 0.1% Tween-80 and snap frozen
in liquid nitrogen. The pellets were stored at −80◦C. The
HTF tagged proteins were then purified, linkers ligated to
crosslinked RNA, cDNA synthesized and DNA libraries
generated as described in (26). The DNA libraries were
then sequenced on the illumina MiSeq platform and
the sequencing output analysed using the pyCRAC tool
package (27).
Northern blotting analysis of tRNA and rRNA after VapC
induction
M. smegmatisMC2155 containing plasmid pMEND-HTF
withVapCof interest were grown exponentially in LBT con-
taining kanamycin (50 g/ml) at 37◦C. At an OD600 of 0.3–
0.4, vapC transcriptionwas induced by the addition of tetra-
cycline (20 ng/ml). A sample was collected before and after
120min of incubationwith inducer. TotalRNAwas purified
using the FastRNABlueKit (MPbiomedicals) according to
manufactures instructions. The cell samples were lysed by
homogenization using the MagNA lyzer (Roche) twice at
6500 rpm for 40 s, separated by a 1 min rest on ice. After
precipitation the RNA was dissolved in nuclease free water.
Total RNA (2.5 g) was denatured in Formamide loading
buffer and separated on a 4.5% (rRNA) or 8% (tRNA) 8M
urea polyacrylamide gel in 1× TBE (100 mM Tris–borate
and 2 mM ethylenediaminetetraacetic acid, EDTA). The
RNAwas then transferred to a Zeta-Probemembrane (Bio-
Rad) by semi-dry electrophoretic transfer and the mem-
brane pre-hybridized with SES1 buffer (0.25 M NaPO4 pH
7.2, 1 mM EDTA and 7% SDS) at 42◦C for at least 30
min. Probe oligonucleotides (20 pmol) (see Supplementary
Table S1) were labelled using 30Ci  32P-ATP and T4
Polynucleotide kinase (Fermentas) according to manufac-
tures procedures and added to the membrane (due to the
high primary sequence similarity between M. smegmatis
and M. tuberculosis tRNAs, M. smegmatis tRNA probes
could be used in most cases except for tRNA24Ser-GGA and
tRNA28Ser-CGA). The tube was then incubated overnight at
29◦C in a hybridization oven. After hybridization the mem-
brane was washed 2–3 times in SES3 buffer (0.25MNaPO4
pH 7.2, 1 mM EDTA and 5% SDS) at room temperature.
The bands were visualized by phosphorimaging. The mem-
brane could be stripped with repeated washes of 0.1% SDS
at 85◦C and subsequently re-probed.
Purification of VapC4-HTF, VapC11-HTF, VapC28-HTF
and VapC37-HTF
VapC toxins were purified from Mycobacterium smeg-
matis using histidine affinity chromatography as we
described previously (22). Mycobacterium smegmatis
MC2155 containing plasmids pMEND::vapC4::HTF,
pMEND::vapC11::HTF, pMEND::vapC28::HTF and
pMEND::vapC37::HTF were grown exponentially in 1-l
LBT at 37◦C with shaking. At OD600 = 0.4, the culture was
induced with tetracycline (20 ng/ml) for 1 h before cells
were pelleted by centrifugation. The cells were then washed
in ice-cold PBS containing 0.1% Tween-80 and lysed in 1 ml
(v/w) lysis buffer (50 mMNaH2PO4, pH 8, 300 mMNaCl,
10 mM Imidazole, 0.1% NP-40, 5 mM -mercaptothanol)
by bead beating (2 × 6500 rpm for 40 s, MagNA lyzer cell
homogenizer) using 0.5 ml 100 M glass beads per 1.5 ml
of cell suspension. The lysate was cleared by centrifugation
at 14 krpm for 20 min and incubated overnight at 4◦C
with 0.5 ml equilibrated Ni-NTA resin (Qiagen). The resin
was then loaded onto a gravity-flow column and washed
with 40 column volume of wash buffer (50 mM NaH2PO4,
pH 8, 300 mM NaCl, 20 mM Imidazole, 0.1% NP-40, 5
mM -mercaptothanol). The column was then washed
with four column volume wash buffer containing 40 mM
imidazole and four column volume wash buffer containing
50 mM imidazole. The protein was eluted by incubating
the column twice with elution buffer (50 mM NaH2PO4,
pH 8, 300 mM NaCl, 500 mM Imidazole, 0.1% NP-40, 5
mM -mercaptothanol). Elution fraction containing VapC
toxin was dialysed for 6 h against PBS containing 1 mM
DTT and overnight against PBS containing 50% glycerol
and 1 mM DTT at 4◦C.
Detection of in vitro RNA cleavage by Northern blotting
analysis
M. smegmatis total RNA was purified using the FastRNA
blue kit (see previous section). To ensure high quality, RNA
was purified by an additional step of phenol/chloroform ex-
traction. TotalRNA fromM. tuberculosisH37Rvwas a gen-
erous gift from Douglas Young and Rachel Lai (National
Institute for Medical Research, London and Imperial Col-
lege London, UK). For the cleavage reaction 1 g or 2.5
g of total RNA was mixed with 1 g or 2 g of puri-
fied VapC4-HTF VapC11-HTF, VapC28-HTF or VapC37-
HTF in cleavage buffer (final: 10 mM HEPES pH7.5, 15
mM KCl, 10 mM MgCl2, 1 mM DTT and 25% glycerol)
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and left to incubate at 37◦C for 30 min. As a control VapC
toxin was omitted in some reactions and Mg2+ chelated by
the addition of 25 mM EDTA. The cleavage reactions were
terminated by addition of FD-loading buffer and the RNA
separated on an 8% Urea polyacrylamide gel buffered with
1× TBE. The RNA was transferred to a Zeta-Probe mem-
brane and the RNA of interest detected using a radiola-
belled probe as previously described.
Mapping of VapC4, VapC11, VapC28 and VapC37 cleavage
site by primer extension analysis
The cleavage reactions were set up as previously described,
using total RNA (4 g) with or without 2 g of puri-
fied VapC4-HTF, VapC11-HTF, VapC28-HTF or VapC37-
HTF. The cleavage reactions were then incubated for 30min
at 37◦C in cleavage buffer. The reaction was terminated by
addition of 400 l 100 mM Na-acetate pH 4.5 followed by
phenol/chloroform extraction and ethanol precipitation.
The precipitate was washed with 70% ethanol, air dried
and dissolved in nuclease free dH2O. The reverse transcrip-
tion was performed by setting up a hybridization reaction
containing 0.2 pmol radiolabelled KW-MS-PXT-CysGCA-
rv, KW-MS-PXT-TrpCCA-rv, KW-MS-PXT-SerTGA-S1-
rv or KW-MS-PXT-LeuCAG-S-rv oligonucleotide and 1
g of purified cleaved RNA in nuclease free dH2O. The
oligonucleotide (4 pmol) was phosphorylated using 30 Ci
 32P-ATP and T4 Polynucleotide kinase (Fermentas) and
subsequently desalted using G-25 desalting columns (GE
healthcare). The hybridization reactions were incubated at
80◦C for 5 min and transferred to an icebath and left to in-
cubate for 5 min. To the chilled reaction 1× FS buffer (In-
vitrogen), 10 mM DTT and 1 mM dNTP was added and
the tube transferred to 54◦C to incubate for 2 min. Then
20 U of Superscript III reverse transcriptase (Invitrogen)
was added and the tubes left to incubate for 1 h. The reac-
tion was terminated by addition of an equal volume of FD-
loading buffer. The reactions were loaded onto a 10% poly-
acrylamide gel containing 8 M urea and 1× TBE. Along
with the reverse transcription reactions a dideoxy sequenc-
ing ladder was loaded which had been made from a PCR
template generated using oligonucleotides KW-MS-PXT-
CysGCA-f and KW-MS-PXT-CysGCA-rv, KW-MS-PXT-
TrpCCA-rv and KW-MS-PXT-TrpCCA-f, KW-MS-PXT-
SerTGA-S1-rv and KW-MS-PXT-SerTGA-f or KW-MS-
PXT-LeuCAG-S-rv and KW-MS-PXT-LeuCAG-f. After
the cDNA had been separated, the gel was dried and the
bands visualized by phosphorimaging.
RESULTS
Identification of cellular VapC targets using CRAC
We implemented CRAC to systematically identify the cel-
lular targets of VapC RNases from M. tuberculosis, using
M. smegmatis as a surrogate host organism. CRAC identi-
fies RNAs that interact directly with a tagged bait protein in
living cells and potentially detects both stable and relatively
transient interactions (26,28). To apply the CRAC proto-
col, all 48 vapC genes ofM. tuberculosisH37Rv (Figure 1A)
were cloned into plasmid pMEND-HTF downstream of a
tetracycline inducible promoter and in frame with a dual
affinity tag that introduced a hexaHis, TEV protease cleav-
age site, and 3× FLAG tags at the C-termini (HTF-tag).
Figure 1B shows the effect of transcriptional induction of
selected vapC genes. Expression of VapC4, 11, 25, 26, 28,
29, 30, 33, 37 and 39 strongly inhibited cell growth, whereas
expression of VapC15 and 32 had a more moderate effect
(for the results of phenotypic testing of all 48 VapCs, see
Supplementary Figure S1A). The pattern of growth inhibi-
tion was generally consistent with previous tests in which
native VapCs were expressed in M. smegmatis (8,29). The
only exception was VapC32 that did not significantly reduce
cell growth in our experimental system (Figure 1B). Thus,
we can conclude that the C-terminal HTF tag does not in-
terfere with VapC-mediated inhibition of cell growth by the
toxins selected in this study.
The majority of VapCs expressed in M. smegmatis
showed weak or no inhibition of growth (Supplementary
Figure S1A). Therefore, we determined the expression levels
of a number of these VapCs (Supplementary Figure S1B).
We found that in some cases, including VapC41, 43 and
44, no VapC expression was detectable 60 min after induc-
tion that could explain the lack of growth inhibition. How-
ever, for the majority of non-toxic VapCs that we tested,
i.e. VapC6, 10, 12, 19, 31 and 47, protein expression was
detectable, indicating that the proteins either are not func-
tional (e.g. the cellular target could be missing in the het-
erologous host). Alternatively, their biological functions do
not entail inhibition of cell growth.
Cultures of M. smegmatis MC2155 were pulsed with
HTF-tagged VapC and were UV-irradiated to covalently
crosslink VapCs to their target RNAs in vivo (Figure 1C).
The covalently bound VapC-RNA complexes were then pu-
rified using M2 anti-FLAG resin, eluted by TEV-cleavage,
and RNAs were trimmed to allow ‘footprinting’ of the
protein interaction site. Trimmed VapC-RNA complexes
were bound to Ni-NTA resin and barcoded linkers were
ligated to the 5′ and 3′ termini. Linker-ligated RNA–
protein complexes were eluted and size-selected using SDS-
PAGE. Protein-RNA complexes of the appropriate molec-
ular weight were extracted and protease digested. cDNAs
were generated by RT-PCR, subjected to deep sequenc-
ing and reads were mapped to the M. smegmatis genome.
VapC binding sites were initially identified using the py-
CRAC software package to identify transcripts bound by
each VapC.We used duplicate controls (pMEND::HTF) to
assess the background of the assay. CRAC data from sam-
ples expressing different VapCs were obtained from single
experiments. The results are shown as reads per million al-
lowing us to visually compare for significance across sam-
ples.
In the following section, we describe the identification
of the cellular targets of previously uncharacterized VapCs.
We will refer to RNA interactions that were confirmed to
conferRNAcleavage as ‘productive interactions’, and other
interactions as ‘unproductive interactions’.
All six VapCs interact with a subset of tRNAs, SRP RNA
and 23S rRNA
Analysis of CRAC data for VapC4, 11, 28, 29, 30
and 37 each revealed enrichment for tRNA5Thr-GGT,
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tRNA8fMet-CAT, tRNA12Val-CAC, tRNA37Asn-GTT and
tRNA31Asp-GTC (Supplementary Figure S2A-E) (the
tRNA nomenclature used is in accordance with GtRNAdb:
http://gtrnadb.ucsc.edu and the reads have been plotted as
per million). However, we were unable to demonstrate that
any of these tRNAs were cleaved by the respective VapCs
when expressed inM. smegmatis cells (Supplementary Fig-
ure S2H-L). The CRAC analysis also revealed enrichment
for SRP RNA and 23S rRNA (Supplementary S2F and
S2G). However, these interactions could not be confirmed
as productive as no cleavage by any of the VapCs was
observed (Supplementary Figure S2M and S2N). VapC28
and VapC29 did indeed showed higher enrichment with the
5′-end region of 23S rRNA (Supplementary Figure S2G)
but we were not able to confirm cleavage in this region of
23S rRNA (Supplementary Figure S2O). As none of these
RNA species were cleaved by VapC4, 11, 28, 29, 30 and 37
we categorize these interactions as unproductive and they
were not studied further.
VapC4 specifically cleaves tRNA44Cys-GCA inM. smegmatis
Analysis of specific RNA interaction with VapC4 using
CRAC revealed strong enrichment for RNA fragments
mapping to tRNA44Cys-GCA (Figure 2A). The interaction
with tRNA44Cys-GCA was productive as the full-length
tRNA decreased upon induction of vapC4 simultaneous
with the accumulation of a smaller cleavage product (com-
pare lanes 1 and 2 with 3 and 4 in Figure 2B). We also ob-
served weak cleavage of tRNA44Cys-GCA before induction
of vapC4. This observation can be explained due to ‘leaky’
transcription initiation from the tetracycline inducible pro-
moter as no cleavage is observed in the control. Induc-
tion of the other vapC toxins did not affect tRNA44Cys-GCA
stability (lanes 5–14). The tRNAs; tRNA23Pro-CGG and
tRNA32Phe-GAA were also specifically enriched by VapC4
(Supplementary Figure S3A and S3B, respectively) but
none of these tRNA species were cleaved by VapC4 (com-
pare lanes 1 and 2 in Supplementary Figure S3D andS3E,
respectively). The other cysteine-accepting tRNA of M.
smegmatis, annotated as tRNA40Cys-GCA, was not enriched
by VapC4 in the analysis, and was not investigated further
(Supplementary Figure S3C).
To confirm that the observed cleavage of tRNA44Cys-GCA
was direct, cleavage was investigated in vitro by Northern
analysis using purified VapC4-HTF in a reaction contain-
ing total RNA from M. smegmatis. Indeed we observed
cleavage of tRNA44Cys-GCA only in the presence of VapC4
(Figure 2C). Consistent with the VapC PIN domain coor-
dinating Mg2+ in the active site, addition of EDTA to the
reaction abolished cleavage. Mapping of the cleavage site
in tRNA44Cys-GCA by primer extension analysis revealed
cleavage in the anticodon loop between bases C34↓A35,
A35↓A36, A36↓A37 and A37↓G38 (arrows indicate cleav-
ages between numbered nucleotides), with theA36↓A37 site
being the dominant cleavage site (Figure 2D and E). The re-
verse transcriptase weakly terminated at this site before ad-
dition of VapC4, probably due to modification of the corre-
sponding base.
VapC4 has recently been suggested to cleave
tRNA2Ala-TGC, tRNA24Ser-GGA, tRNA26Ser-GCT of M.
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Figure 2. VapC4 cleaves tRNA44Cys-GCA in M. smegmatis. (A) Enrich-
ment of tRNA44Cys-GCA fragments by six different VapCs (VapC4, 11, 28,
29, 30 and 37) analysed by CRAC.M. smegmatis strain MC2155 contain-
ing plasmid pMEND::HTF was used as a Control. The X-axis indicates
nucleotide position relative to gene start site and Y-axis shows number of
reads per million. (B) Northern analysis of tRNA44Cys-GCA cleavage. M.
smegmatis containing plasmid pMEND::HTF with six different vapC as
in (A) were grown exponentially in LBT at 37◦C. At an OD600 of 0.3–
0.4, the vapC gene was induced by the addition of tetracycline (20 ng/ml).
Total RNA was purified from samples taken before (indicated by 0) and
after 120 min of induction (indicated by 120). Total RNA (2.5 g) was
separated on a polyacrylamide gel (8%) containing urea (8 M) and blotted
onto a membrane and the tRNAs of interest detected using radiolabelled
oligonucleotides detecting tRNA44Cys-GCA. Full-length tRNA44Cys-GCA
is indicated and the cleavage product is indicated with an arrow. (C) in
vitro cleavage of M. smegmatis tRNA44Cys-GCA by purified VapC4-HTF
(addition of protein is indicated with a +) detected by Northern analysis
as described in Materials and Methods. A reaction with EDTA was in-
cluded as a control for dependency on Mg2+. FL indicates the position of
the full-length tRNAand the cleavage product is indicated by an arrow. (D)
Cleavage site mapping of tRNA44Cys-GCA by primer extension analysis in
the absence (indicated by –) and presence (indicated by +) of VapC4-HTF
as described in Materials and Methods, using the 32P-labelled oligonu-
cleotide MS-PXT-Cys-GCA-rv. An asterisk indicates the position of a pu-
tative modification in the tRNA. (E) Visualization of the VapC4-mediated
in vitro cleavage sites on the secondary structure of tRNA44Cys-GCA. The
base positions of the cleavage sites are indicated in the anticodon loop.
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tuberculosis H37Rv in vitro (30). We did observe weak
enrichment of tRNA24Ser-GGA tRNA26Ser-GCT by VapC4
(Supplementary Figure S4E and S4F). However, we did
not observe any cleavage of these tRNA species in vivo
(compare lane 1 and 2, Supplementary Figure S3F-H).
We also did not observe cleavage of tRNA24Ser-GGA or
tRNA26Ser-GCT in vitro with M. smegmatis RNA (Supple-
mentary Figure S3I and S3J) or in vitrowithM. tuberculosis
H37Rv RNA (Supplementary Figure S3K and S3L).
VapC11 cleaves tRNA3Leu-CAG, tRNA13Leu-GAG and
tRNA10Gln-CTG
CRAC analysis showed enrichment for RNA frag-
ments derived from tRNA3Leu-CAG, tRNA13Leu-GAG and
tRNA10Gln-CTG by VapC11 (Figure 3A-C). These inter-
actions were productive since tRNA cleavage products
accumulated upon vapC11 induction in all three cases
(compare lanes 1 and 2 with 5 and 6 in Figure 3D–F).
None of the other VapCs tested showed productive inter-
actions with these tRNA species (lanes 3, 4 and 7–14).
The positive interaction with tRNA3Leu-CAG seemed to
be strongest as a cleavage product could be detected even
before induction of vapC11 (lane 5), probably reflecting
leakiness of the tetracycline-inducible promoter driving
vapC11 transcription.
To determine whether the activity of VapC11 was di-
rect, we assayed cleavage of tRNA3Leu-CAG in vitro. Purified
VapC11-HTF was incubated with total RNA of M. smeg-
matis. Northern analysis confirmed that tRNA3Leu-CAG was
cleaved by VapC11, with accumulation of a discrete cleav-
age product (Figure 3G). Cleavage was inactivated by the
addition of EDTA, demonstrating that the cleavage activ-
ity wasMg2+ dependant. Primer extension analysis revealed
that VapC11 cleaved tRNA3Leu-CAG in the anticodon loop
between nucleotide pairs G37↓U38, and U38↓G39, respec-
tively (Figure 3H and I). Like tRNA44Cys-GCA cleavage by
VapC4 we observe termination of the reverse transcriptase
at these sites before addition of VapC11 indicating that the
sites are putative sites of modification.
VapC28 and VapC30 both cleave tRNA25Ser-TGA and
tRNA28Ser-CGA
VapC28 and VapC30 specifically enriched for RNA frag-
ments derived from tRNA25Ser-TGA, tRNA28Ser-CGA (Com-
pare lanes 1 and 2 with 7 and 8 and 11 and 12 of
Figure 4A and B). Induction of vapC28 and vapC30
showed reduced amounts of full-length tRNA25Ser-TGA
and tRNA28Ser-CGA. However, stable, discrete cleavage
products were not detected (compare lane 1–2 with 7–
8 and 11–12 Figure 4C and D). Expression of the other
VapCs analysed by CRAC did not affect the stabil-
ity of tRNA25Ser-TGA and tRNA28Ser-CGA. CRAC anal-
ysis also revealed tRNA43Gly-GCC, tRNA17Lys-CTT and
tRNA2Ala-TGC to be enriched by VapC28 andVapC30 (Sup-
plementary Figure S4A-C). However, none of these tR-
NAs were detectably affected by induction of vapC28 and
vapC30 and these interactions were categorized as un-
productive (Supplementary Figure S4H-J, compare lane
1 and 2). Furthermore, CRAC analysis revealed enrich-
ment of tRNA16His-GTG, tRNA24Ser-GGA, tRNA26Ser-GCT
and tRNA22Thr-TGT by VapC30 alone (Supplementary Fig-
ure S4D–G). These enrichments were also categorized as
unproductive as no changes in stabilities were observed af-
ter induction of VapC30 (compare lanes 1 and 2 in Supple-
mentary Figure S4K–N).
The activity of VapC28 was confirmed by in vitro cleav-
age. Thus, VapC28 cleaved tRNA25Ser-TGA ofM. smegmatis
(Figure 4E) and a discrete cleavage product was detected,
suggesting that the absence of clear cleavage product in vivo
reflected their rapid degradation. Addition of EDTA abol-
ished cleavage, consistent with the requirement for Mg2+ in
the reaction. The cleavage site of VapC28 in tRNA25Ser-TGA
was mapped to nucleotide pairs G36↓A37 in the anticodon
loop (Figure 4F and G). At A38, we observed strong ter-
mination of reverse transcriptase before the addition of
VapC28, probably reflecting base modification at this po-
sition.
VapC29 and VapC37 cleave tRNA7Trp-CCA
CRAC with VapC29 and VapC37 as baits identified inter-
actions with RNA fragments derived from tRNA7Trp-CCA
(Figure 5A). In addition, VapC29 also specifically enriched
for tRNA4Tyr-GTA-derived fragments while VapC37 specifi-
cally enriched for tRNA42Leu-CAA-derived fragments (Sup-
plementary Figure S5A and S5B). Northern analysis re-
vealed productive interactions between tRNA7Trp-CCA and
VapC29 and VapC37 inM. smegmatis cells and two discrete
cleavage products accumulated upon induction (compare
lanes 1 and 2 with lanes 9 and 10 and 13 and 14 of Figure
5B). None of the other VapCs analysed by CRAC was ob-
served to affect the stability of this tRNA (lanes 3–8 and
11–12). Neither tRNA4Tyr-GTA nor tRNA42Leu-CAA were
cleaved by VapC29 and VapC37, respectively, and these in-
teractions were therefore categorized as unproductive (com-
pare lanes 1 and 2 in Supplementary Figure S5C and S5D).
Incubation of purified VapC37 with total RNA ofM. smeg-
matis confirmed direct cleavage of tRNA7Trp-CCA that was
Mg2+ dependent (Figure 5C). We only observe one cleav-
age product in vitro, indicating that the two cleavage prod-
ucts observed in vivo is a result of cellular RNases similar
to that observed for tRNA25Ser-TGA and tRNA28Ser-CGA.
The VapC37 cleavage sites in tRNA7Trp-CCA were mapped
to bases A36↓A37, A37↓A38 and A38↓A39, with the
A37↓A38 cleavage site being the most prominent (Figure
5D and E). Similar to the other tRNAs mapped by primer
extension analysis we observe termination of reverse tran-
scription reaction in this region before addition of VapC37,
which indicates a putative site of modification in the tRNA
at the cleavage site.
VapC4, VapC11, VapC28 and VapC37 cleave orthologous
tRNAs inM. tuberculosis
The above-described in vitro cleavage reactions were per-
formed using total RNA from M. smegmatis as the sub-
strate. Even though the tRNAs ofM. smegmatis are almost
identical to the orthologous tRNAs ofM. tuberculosis there
are nucleotide differences that potentially could affect VapC
recognition and cleavage (Supplementary Figure S6A–G).
The VapC cleavage reactions were therefore also analysed
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Figure 3. VapC11 cleaves tRNA3Leu-CAG, tRNA10Leu-GAG and tRNA13Gln-CTG inM. smegmatis. Enrichment of (A) tRNA3Leu-CAG, (B) tRNA10Leu-GAG
and (C) tRNA13Gln-CTG by six different VapCs analysed by CRAC as in Figure 2 (A). In vivo cleavage by six VapCs was analysed as in Figure 2(B) and
the tRNAs of interest detected using radiolabelled oligonucleotides complementary to (D) tRNA3Leu-CAG. (E) tRNA13Leu-GAG. (F) tRNA10Gln-CTG. The
tRNAs were analysed before (indicated by 0) and after 120 min of induction (indicated by 120) inM. smegmatis cells. Cleavage products are indicated with
arrows. (G) in vitro cleavage assay of tRNA3Leu-CAG without (indicated by –) or with (indicated by +) purified VapC11-HTF detected by Northern analysis
as in Figure 2(C). A reaction with EDTA was included as a control for dependency on Mg2+. (H) Cleavage site mapping by primer extension analysis was
performed as in Figure 2 (D), using the 32P-labeled oligonucleotideMS-PXT-LeuCAG-S-rv. An asterisk indicates the position of a putative modification in
the tRNA. (I) Visualization of the VapC11-mediated in vitro cleavage sites on the secondary structure of tRNA3Leu-CAG. The base positions of the cleavage
sites are indicated in the anticodon loop.
using total RNA ofM. tuberculosisH37Rv. Consistent with
our results inM. smegmatis, VapC4 cleaved tRNA21Cys-GCA
(Figure 6A, lanes 2 and 3), VapC11 specifically cleaved
tRNA3Leu-CAG (Figure 6B, lane 2), VapC28 specifically
cleaved tRNA25Ser-TGA and tRNA28Ser-CGA (Figure 6C and
D, lane 5) and VapC37 specifically cleaved tRNA7Trp-CCA
(Figure 6E, lane 8). The cleavages were tRNA-specific and
all cleavages were also inhibited by the EDTA addition,
indicating Mg2+ dependence (Figure 6B–E). These results
confirmed that heterologously expressed VapCs have iden-
tical cleavage specificities in M. smegmatis, validating this
organism as a useful surrogate host for the analysis of VapC
toxins fromM. tuberculosis.
Phylogeny can predict novel VapC targets
The identification of novel VapC targets is challenging and
in the past required the application of laborious ‘trial-and-
error’ approaches. SinceM. tuberculosis has at least 48 dif-
ferent VapCs (Figure 1A), we tested the possibility that the
targets we had identified could provide insights into the tar-
gets of related VapC toxins using a phylogenetic approach.
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Figure 4. VapC28 andVapC30 cleave tRNA25Ser-TGA and tRNA28Ser-CGA
of M. smegmatis. Enrichment of tRNA fragments from (A)
From the phylogenetic tree shown in Supplementary Figure
S1C, we selected six VapCs that group together with one of
the VapCswith a known target, identified here or in our pre-
vious analysis (22), and tested whether these VapCs cleaved
the same targets. The following examples showed that this
approach was effective.
(i) VapC15 and VapC32 cleave tRNA3Leu-CAG. VapC15 and
VapC32 group together with VapC11 in the phylogram
(Figure 7E and Supplementary Figure S1C). Therefore,
we asked if these twoVapCs also cleave tRNA3Leu-CAG, the
tRNA that was cleavedmost efficiently byVapC11. Indeed
tRNA3Leu-CAG was cleaved upon induction of vapC15 and
vapC32 (Figure 7A, lanes 3 - 6). These cleavages were rela-
tively weak compared to those of VapC11, consistent with
the lower toxicity of these VapCs inM. smegmatis (Figure
1B). VapC11 was also found to have productive interac-
tions with tRNA13Leu-GAG and tRNA10Gln-CTG, but these
tRNA species were not cleaved by VapC15 or VapC32
(Supplementary Figure S7A and S7B).
(ii) VapC25, 33 and 39 cleave tRNA7Trp-CCA. VapC25, 33
and 39 group together with VapC29 and 37 in the phy-
logram (Figure 7E and Supplementary Figure S1C) and
induction of these toxins in M. smegmatis inhibited cell
growth (Figure 1B). Notably, induction of vapC25, 33
or 39 resulted in cleavage products identical to those of
VapC29 and 37 (Figure 7B lanes 3 - 8).
(iii) VapC26 cleaves 23S rRNA in the Sarcin–Ricin Loop
(SRL). VapC26 groups with VapC20 in the phylogram
(Figure 7E and Supplementary Figure S1C) and inhibited
growth ofM. smegmatis very efficiently (Figure 1B). Since
VapC20 cleaves 23S rRNA in the SRL loop (22), we tested
if VapC26 also cleaves 23S rRNA. Indeed, induction of
vapC26 resulted in a 23S rRNA cleavage pattern identical
to that of VapC20 showing that the two VapCs have iden-
tical targets (Figure 7C, lanes 3–6).
VapCs are highly target-specific
The above results indicated that VapCs grouping together
phylogenetically exhibit identicalRNAcleavage specificities
(Figure 7E and Supplementary Figure S1C). Therefore, we
analysed whether VapCs from one phylogenetic subgroup
would cleave RNAs targeted by a different VapC subgroup.
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
tRNA25Ser-TGA and (B) tRNA28Ser-CGA by six VapCs was identi-
fied by CRAC as described before. Detection of in vivo cleavage by
VapCs were investigated as in Figure 2(B) before (indicated by 0) and
after 120 minutes of induction (indicated by 120). The tRNA of interest
was detected using radiolabelled oligonucleotides complementary to
(C) tRNA25Ser-TGA and (D) tRNA28Ser-CGA. (E) Cleavage in vitro of
tRNA25Ser-TGA was determined as Figure 2(C) in the absence (indicated
by –) and in the presence (indicated by +) of purified VapC28-HTF. The
cleavage product was detected by Northern analysis using a radiolabelled
probe specific to tRNA25Ser-TGA. (F) The in vitro cleavage sites in
tRNA25Ser-TGA were mapped as in Figure 2(D) using radiolabelled
oligonucleotide MS-PXT-SerTGA-S1-rv in the reverse transcription
reaction of VapC28 in vitro cleaved RNA from M. smegmatis. Absence
or presence of VapC28-HTF is indicated by a – or +, respectively
and the mapped cleavage site position is indicated with an arrow. An
asterisk indicates the position of a putative modification in the RNA. (G)
Visualization of the cleavage site in tRNA25Ser-TGA. The base position
and cleavage site are indicated in the anticodon loop.
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Figure 5. VapC29 and VapC37 cleave tRNA7Trp-CCA of M. smegma-
tis. (A) Enrichment of tRNA fragments from tRNA7Trp-CCA by six
VapCs was identified by CRAC as described previously. (B) Cleavage of
tRNA7Trp-CCA in M. smegmatis cells expressing VapCs was detected by
Northern analysis as described before. Samples taken before and after 120
min of induction are indicated by 0 and 120, respectively and cleavage
products are indicated with arrows. (C) In vitro cleavage of tRNA7Trp-CCA
without (indicated by –) and with (indicated by +) purified VapC37-HTF
was performed as in Figure 2(C) and cleavage detected using a radiola-
belled probe specific to tRNA7Trp-CCA. (D) The in vitro cleavage site in
tRNA7Trp-CCA was mapped as in Figure 2(D) using radiolabelled DNA
oligonucleotide MS-PXT-TrpCCA-rv in the reverse transcription reaction
and total RNA of M. smegmatis treated without (indicated by –) or with
(indicated by +) VapC37-HTF. Arrows indicate cleavage sites and an aster-
isk indicates the position of a putative modification in the tRNA. (E) Visu-
alization of the cleavage sites in tRNA7Trp-CCA. Base position and cleavage
sites are indicated in the anticodon loop.
As seen from both in vivo (see overview in Supplementary
Figure S8A–G) and in vitro cleavage assays (see overview
in Supplementary Figure S9A-D) we observed no cross-
reactivity and conclude that the VapCs analysed are highly
specific endoribonucleases.
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Figure 6. VapC4, VapC11, VapC28 and VapC37 cleave orthologous tR-
NAs in M. tuberculosis. In vitro cleavage of M. tuberculosis H37Rv tR-
NAs by purified VapC4, 11, 28 and 37 detected by Northern anal-
ysis was performed as described in Materials and Methods. Addi-
tion of toxins and EDTA are indicated by (+) and arrows indicate
cleavage products. For reactions containing toxin (+) indicated addi-
tion of 1g of toxin, whereas (++) indicated addition of 2g. The
membrane was incubated with tRNA specific DNA probe hybridizing
to (A) tRNA21Cys-GCA. (B) tRNA3Leu-CAG. (C) tRNA25Ser-TGA. (D)
tRNA28Ser-CGA. (E) tRNA7Trp-CCA ofM. tuberculosis H37Rv.
DISCUSSION
Using CRAC in combination with phylogenetic analysis
and in vivo and in vitro RNA cleavage assays, we identi-
fied the cellular targets of 12 novel VapCs from M. tu-
berculosis H37Rv. UV-crosslinking and high throughput
sequencing revealed binding sites that were both produc-
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Figure 7. Phylogeny can predict cellular VapC targets. (A) Detec-
tion of in vivo cleavage of tRNA3Leu-CAG by VapC15 and VapC32
by Northern analysis was performed as in Figure 3 (D); VapC ex-
pression was induced from M. smegmatis MC2155 carrying plasmids
pMEND::vapC15::HTF or pMEND::vapC32::HTF. (B) in vivo cleav-
age of tRNATrp-CCA by VapC25, VapC33 and VapC39 was detected by
Northern analysis performed as in Figure 5 (B). Toxin expression was
induced from plasmid pMEND::vapC25::HTF, pMEND::vapC33::HTF
and pMEND::vapC39::HTF. (C) Cleavage of 23S rRNA detected by
Northern analysis was performed on RNA purified from M. smeg-
matis strain MC2155 containing plasmids pMEND::vapC20::HTF and
pMEND::vapC26::HTF. Cell samples were collected before (indicated by
0) and after 120min of induction (indicated by 120) and analysed as de-
scribed in Materials and Methods. The arrow indicates the 276 nucleotide
cleavage product of 23S rRNA generated by VapC20 and VapC26, as
mapped previously (22). The full-length 23S rRNA (3164 nt) is also in-
dicated with an arrow. (D) Region of the decoding center of 70S ribosome
tive (cleaved) and apparently unproductive (Supplementary
Figure S2). Functional tests identified site-specific tRNA
cleavage sites for six VapCs. Using a phylogenetic approach,
we exploited this novel information to identify specific tar-
gets for six additional VapCs. Since the target of VapC20
was already known (22), collectively we now know the tar-
gets of thirteen of the forty-eight VapCs of M. tuberculo-
sis (Figure 7E and Supplementary Figure S1C). Remark-
ably, all these thirteen VapCs degrade RNAs that are essen-
tial for translation: eleven VapCs cleave tRNAs while two
VapCs cleave the SRL of 23S rRNA. These RNA cleav-
ages all inactivate RNAs essential for mRNA decoding
at the A-site during translation (Figure 7D), thereby ex-
plaining the strong growth inhibition resulting from their
overexpression. Together with previous reports, our data
show that VapCs from different bacterial domains (actino-
mycetes, spirochaetes and enterobacteria) inhibit transla-
tion by highly related mechanisms, indicating conserved bi-
ological function(s) (20,22). Moreover, phylogenetic anal-
yses determined that evolutionarily related VapC pro-
teins show identical cleavage specificities, indicating a de-
gree of functional redundancy. Within the VapC11/15/32
clade, VapC11 additionally cleaved tRNA13Leu-GAG and
tRNA10Gln-CTG (Figure 7E). However, the cleavages of
these tRNAs by VapC11 were less efficient (Figure 3E and
F) and may represent an artefact of ectopic expression of
VapC11 caused by the high sequence similarity of the anti-
codon loops (Supplementary Figure S6B–D).
Cruz et al. recently reported cleavage of tRNA2Ala-TGC,
tRNA24Ser-GGA, tRNA26Ser-GCT by VapC4 (30). In our
study we did not observe enrichment of tRNA2Ala-TGC by
VapC4 (Supplementary Figure S4C) and, consistently, we
did not observe cleavage of this tRNA when VapC4 was in-
duced in M. smegmatis cells (Supplementary Figure S3F).
We did indeed observe weak enrichment of RNA fragments
from tRNA24Ser-GGA and tRNA26Ser-GCT by CRAC with
VapC4 as the bait (Supplementary Figure S4E and S4F);
however, no cleavage of tRNA24Ser-GGA or tRNA26Ser-GCT
by VapC4 was observed in vivo (Supplementary Figure
S3G and S3H) or in vitro (Supplementary Figure S3I-
L). We note that the reported cleavage of tRNA2Ala-TGC,
tRNA24Ser-GGA, and tRNA26Ser-GCT by VapC4 in vitro was
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
of Thermus thermophilus in complex with mRNA and the ternary complex
of EF-Tu•Thr-tRNAThr•GDP (pdb entry: 4V5G from (31)). The Figure
highlights that VapCs ofM. tuberculosis cleave RNAs essential for decod-
ing during translation. The Sarcin - Ricin Loop (SRL), which is cleaved by
VapC20 and 26, is shown in orange. The tRNA anticodon loop, which is
cleaved by VapC4, 11, 15, 25, 28, 29, 30, 32, 33 37 and 39, is also marked
with a box. Bases cleaved are coloured red. Major parts of the ribosome
structures were omitted for clarity. (E) Phylogenetic tree of VapCs of M.
tuberculosis strain H37Rv with known targets was based on a multiple
sequence alignment made using the ClustalX v2.0 software; amino acid
sequences were retrieved from www.ncbi.nlm.nih.gov. VapCMYSH: VapC
from Shigella flexneri 2a plasmid pMYSH6000 (21). VapCLepto: VapC of
Leptospira interrogans (20). The tRNAs in the green, magenta, blue and
light blue boxes have identical names inM. smegmatisMC2155 andM. tu-
berculosisH37Rv except tRNA13Leu-CAG and tRNA10Gln-CTG ofM. smeg-
matis that are denoted tRNA15Leu-CAG and tRNA32Gln-CTG inM. tuber-
culosisH37Rv. tRNA44Cys-GCA inM.smegmatis is named tRNA21Cys-GCA
inM. tuberculosisH37Rv. The sequences of the orthologous tRNAs stud-
ied here are shown in Supplementary Figure S6.
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only seen after highly extended incubation times only (3-
12hr; (30)), raising the possibility that these tRNAs repre-
sent low-affinity targets of VapC4. Using UV-crosslinking
and Northern analysis we found that VapC4 actually in-
teracts with, and cleaves tRNA44Cys-GCA in vivo. We used a
much shorter incubation time (30 min) and exclusively ob-
served cleavage of tRNA44Cys-GCA ofM. smegmatis and the
orthologous tRNA21Cys-GCA ofM. tuberculosis H37Rv.
In enterobacteria, TA gene modules encoding trans-
lational inhibitors promote increased survival following
exposure to antibiotics or stressful conditions within
macrophages (11–15,32). The biological function(s) of the
multitude of vapBC modules encoded by M. tuberculosis
has not yet been established. However, it is possible that
cleavage of RNAs essential for translation similarly confers
protection by inhibiting cell growth, as proposed previously
by other groups (8,16,17,33). Consistent with this proposal,
E. coli rapidly responds to oxidative stress by downregulat-
ing translation via tRNA degradation (34). It is also possi-
ble that the vapBC genes can prevent bacteriophages from
spreading in cell populations by inducing so-called ‘abortive
infection’ that has been described for type III TA modules
also encoding inhibitors of translation (35,36).
The M. tuberculosis genome contains an unusually large
expansion of TA modules that present a unique challenge
for understanding their contribution to bacterial persis-
tence in this significant human pathogen. Here we de-
scribed a newmethodology to identify the cellular targets of
PIN-domain RNases in vivo and demonstrated that related
clades of VapC toxins have similar substrate specificities. To
our knowledge this study represents the most comprehen-
sive analysis of VapC targets to date and greatly expands
our understanding of VapC targets inM. tuberculosis.
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